DAVENPORT & Co LLC Purchases 5,264 Shares of Prestige Consumer Healthcare Inc. $PBH

Key Points

• DAVENPORT & Co LLC increased its holdings in Prestige Consumer Healthcare by 34.0%, bringing their total to 20,728 shares valued at approximately $1.655 million.
• Prestige Consumer Healthcare reported $0.95 EPS for the latest quarter, missing expectations by $0.06, with a revenue of $249.53 million compared to anticipated $260.71 million.
• Analyst ratings for Prestige Consumer Healthcare are mixed, with four "Buy" ratings, two "Hold" ratings, and one "Sell" rating, while the company has a current average price target of $94.80.

DAVENPORT & Co LLC grew its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 34.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,728 shares of the company's stock after acquiring an additional 5,264 shares during the quarter. DAVENPORT & Co LLC's holdings in Prestige Consumer Healthcare were worth $1,655,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in shares of Prestige Consumer Healthcare by 35.9% during the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock worth $162,000 after purchasing an additional 496 shares during the period. KBC Group NV lifted its holdings in Prestige Consumer Healthcare by 7.4% in the 1st quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after purchasing an additional 151 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in Prestige Consumer Healthcare by 8.6% in the 1st quarter. QRG Capital Management Inc. now owns 5,971 shares of the company's stock valued at $513,000 after purchasing an additional 475 shares in the last quarter. Intech Investment Management LLC lifted its holdings in Prestige Consumer Healthcare by 18.9% in the 1st quarter. Intech Investment Management LLC now owns 27,307 shares of the company's stock valued at $2,348,000 after purchasing an additional 4,343 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in Prestige Consumer Healthcare by 354.0% in the 1st quarter. XTX Topco Ltd now owns 22,778 shares of the company's stock valued at $1,958,000 after purchasing an additional 17,761 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $62.67 on Friday. The stock has a 50-day simple moving average of $65.53 and a 200-day simple moving average of $76.37. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The stock has a market capitalization of $3.08 billion, a PE ratio of 14.71, a PEG ratio of 2.00 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a 1 year low of $61.28 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). The company had revenue of $249.53 million during the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The business's quarterly revenue was down 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PBH. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Prestige Consumer Healthcare in a research note on Wednesday. Sidoti raised Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 price objective for the company in a research report on Wednesday, September 24th. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Zacks Research downgraded Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Finally, Canaccord Genuity Group cut their price objective on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $94.80.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.